Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Immunomedics, Inc.    IMMU

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Immunomedics To Receive $16.7 Million Payment to Resolve Finra Proceedings

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/02/2013 | 12:11am CET
   By Kristin Jones 
 

Immunomedics Inc. (>> Immunomedics, Inc.) expects to receive a total payment of $16.7 million after reaching a settlement with its former broker, resolving allegations the drug company had brought to the Financial Industry Regulatory Authority related its investments.

Immunomedics said Monday that it will receive a gross settlement amount of $18 million, excluding expenses and legal fees, and has agreed to dismiss the proceeding with prejudice against an unnamed broker.

The company has said in filings that in 2009, it initiated an arbitration proceeding before Finra against its former investment advisor, former Bank of America Corp. (>> Bank of America Corp) units Banc of America Investment Services Inc. and Banc of America Securities LLC. Immunomedics accused the firm of making false representations or omissions concerning auction rate securities.

A representative from Bank of America wasn't immediately available for comment.

Immunomedics focuses primarily on the development of treatments for cancer and other serious diseases.

Its shares closed Monday up 1.2% at $2.44 and were unchanged after hours. The stock is down 16% since the start of the year.

Write to Kristin Jones at kristin.jones@dowjones.com

Stocks mentioned in the article : Immunomedics, Inc., Bank of America Corp
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMMUNOMEDICS, INC.
01/19 IMMUNOMEDICS : Highlights Expanded Pipeline Positioning Company for Sustained Va..
01/19 IMMUNOMEDICS : Announces New Data for IMMU-132 at Investor R&D Day
01/18 IMMUNOMEDICS : CORRECTING and REPLACING venBio Sends Letter to Immunomedics Stoc..
01/18 Immunomedics Highlights Expanded Pipeline Positioning Company for Sustained V..
01/18 IMMUNOMEDICS INC : Regulation FD Disclosure, Financial Statements and Exhibits (..
01/18 Immunomedics Announces New Data for IMMU-132 at Investor R&D Day
01/12 IMMUNOMEDICS INC : Change in Directors or Principal Officers (form 8-K)
01/12 IMMUNOMEDICS : to Mail Letter to Stockholders Highlighting Unprecedented Progres..
01/12 Immunomedics to Mail Letter to Stockholders Highlighting Unprecedented Progre..
01/11 VENBIO : Sends Letter to Immunomedics Stockholders
More news
Sector news : Biotechnology & Medical Research - NEC
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
01/20 After Hours Gainers / Losers
01/18 Immunomedics (IMMU) CEO Cynthia Sullivan Hosts Analyst Day - Slides
01/18 New data on Immunomedics' lead ADC candidate IMMU-132 still positive; U.S. ma..
01/05 Jefferies says familiar names will be the strongest biotechs this year
2016 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
Advertisement
Financials ($)
Sales 2017 14,9 M
EBIT 2017 -
Net income 2017 -
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 31,7x
Capi. / Sales 2018 13,5x
Capitalization 473 M
More Financials
Chart IMMUNOMEDICS, INC.
Duration : Period :
Immunomedics, Inc. Technical Analysis Chart | IMMU | US4529071080 | 4-Traders
Full-screen chart
Technical analysis trends IMMUNOMEDICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 6,00 $
Spread / Average Target 35%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Cynthia L. Sullivan President, Chief Executive Officer & Director
David M. Goldenberg Chairman, Chief Scientific & Patent Officer
Michael R. Garone Chief Financial Officer & Vice President-Finance
William A. Wegener Chief Medical Officer
Brian A. Markison Lead Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOMEDICS, INC.21.53%473
INCYTE CORPORATION17.21%22 141
QUINTILES IMS HOLDINGS..0.03%18 727
CELLTRION, INC.--.--%10 532
LONZA GROUP AG4.14%9 648
ALKERMES PLC0.90%8 523
More Results